In the Claims:

This listing of claims replaces all prior versions of claims in the application:

1 (currently amended). A compound having structure [[I or]] II as indicated below except the compound of Formula (II) with provided that R2 and R3 are not 2-thiophene when R4 is -OC(O)CH₃:

$$R1$$
 $R3$
 $R4$
 $R2$
 $R3$
 $R4$
 $R2$

wherein:

the H atom indicated is in the exo position;

R1⁻ represents an anion associated with the positive charge of the N atom. R1⁻ may be but is not limited to chloride, bromide, iodide, sulfate, benzene sulfonate or toluene sulfonate;

R2 and R3 are independently selected from the group consisting of straight or branched chain lower alkyl groups (having preferably from 1 to 6 carbon atoms), cycloalkyl groups (having from 5 to 6 carbon atoms), eycloalkyl-alkyl (having 6 to 10 carbon atoms), heterocycloalkyl (having 5 to 6 carbon atoms) and N or O as the heteroatom, heterocycloalkyl-alkyl (having 6 to 10 carbon atoms) and N or O as the heteroatom, aryl, optionally substituted aryl, and heteroaryl;

R4 is sleected selected from the group consisting of (C_1-C_6) alkyl, (C_3-C_{12}) cycloalkyl, (C_3-C_{12}) cycloalkyl, (C_3-C_{12}) cycloalkyl, (C_1-C_6) alkyl (C_3-C_{12}) cycloalkyl, (C_1-C_6) alkyl (C_3-C_7) heterocycloalkyl, aryl, heteroaryl, (C_1-C_6) alkyl-aryl, (C_1-C_6) alkyl-heteroaryl, -OR5, $-CH_2OR5$, $-CH_2OH$, -CN, $-CF_3$, $-CH_2O(CO)R6$, $-CO_2R7$, $-CH_2NH_2$, $-CH_2N(R7)SO_2R5$, $-SO_2N(R7)(R8)$, -CON(R7)(R8), $-CH_2N(R8)CO(R6)$, $-CH_2N(R8)SO_2(R6)$, $-CH_2N(R8)CO_2(R5)$, and $-CH_2N(R8)CONH(R7)$;

R5 is selected from the group consisting of (C_1-C_6) alkyl, (C_1-C_6) alkyl (C_3-C_{12}) cycloalkyl, (C_1-C_6) alkyl (C_3-C_7) heterocycloalkyl, (C_1-C_6) alkyl-aryl, (C_1-C_6) alkyl heteroaryl;

R6 is selected from the group consisting of (C_1-C_6) alkyl, (C_3-C_{12}) cycloalkyl, (C_3-C_{12}) cycloalkyl, (C_4-C_6) alkyl (C_3-C_7) heterocycloalkyl, aryl, heteroaryl, (C_1-C_6) alkyl-aryl, (C_1-C_6) alkyl-heteroaryl;

R7 and R8 are, independently, selected from the group consisting of [[H]] <u>hydrogen</u>, (C_1-C_6) alkyl, (C_3-C_{12}) cycloalkyl, (C_3-C_7) heterocycloalkyl, (C_1-C_6) alkyl (C_3-C_1) cycloalkyl, (C_1-C_6) alkyl (C_3-C_7) heterocycloalkyl, (C_1-C_6) alkyl-aryl, and (C_1-C_6) alkylheteroaryl.

Claims 2 to 13 (Cancelled).

14 (new). The compound according to Claim 1 wherein

R2 and R3 are independently selected from the group consisting of aryl, or heteroaryl; R4 is selected from the group consisting of aryl, OR5, CH₂OR5, CH₂OH, CN, CO₂R7, CH₂N(R7)SO₂R5, CONR7R8, CH₂N(R8)CO(R6), CH₂N(R8)SO₂(R6), CH₂N(R8)CO₂(R5), CH₂N(R8)CONH(R7);

R5 is a (C_1-C_6) alkyl;

R6 is selected from the group consisting of (C_1-C_6) alkyl or aryl; and R7 and R8 independently selected from the group consisting of hydrogen, or (C_1-C_6) alkyl.

- 15 (new). The compound according to Claim 1 wherein R2 and R3 are independently selected from the group consisting of aryl, or heteroaryl.
- 16 (new). The compound according to Claim 15 wherein R2 and R3 are both aryl.
- 17 (new). The compound according to Claim 16 wherein R2 and R3 are both phenyl.
- 18 (new). The compound according to Claim 17 wherein R4 is cyano.
- 19 (new). The compound according to Claim 14 wherein R2 and R3 are both aryl.

20 (new).	The compound according to Claim 19 wherein R2 and R3 are both phenyl.
21 (new).	The compound according to Claim 20 wherein R4 is cyano.
22 (new).	The compound according to Claim 14 wherein R4 is cyano.
23 (new).	The compound according to Claim 15 wherein R2 and R3 are both heteroaryl.
24 (new).	The compound according to Claim 23 wherein R2 and R3 are both thienyl.
25 (new).	The compound according to Claim 14 wherein R2 and R3 are both heteroaryl.
26 (new).	The compound according to Claim 25 wherein R2 and R3 are both thienyl.
27 (new).	The compound according to Claim 14 wherein R4 is CONR7R8.
28 (new).	The compound according to Claim 27 wherein R7 and R8 are both hydrogen.
29 (new). aryl.	The compound according to Claim 14 wherein -CH $_2$ N(R8)SO $_2$ (R6) and R6 is
30 (new). R6 is aryl or (C	The compound according to Claim 14 wherein R4 is $-CH_2N(R8)CO(R6)$, and C_1-C_6) alkyl.
31 (new). CH ₂ OH.	The compound according to Claim 14 wherein R4 is OR5, CH ₂ OR5, and
32 (new).	The compound according to Claim 31 wherein R5 is methyl.
33 (new).	The compound according to Claim 14 wherein R4 is CO ₂ R7, and R7 is hydrogen.
34 (new). methyl.	The compound according to Claim 14 wherein R4 is $CH_2N(R7)SO_2R5$ and R5 is

- 35 (new). The compound according to Claim 14 wherein R4 is $CH_2N(R8)CO(R6)$, R8 is hydrogen, and R6 is aryl.
- 36 (new). The compound according to Claim 14 wherein R4 is $CH_2N(R8)CONH(R7)$, R8 is hydrogen, and the R7 is (C_1-C_6) alkyl.
- 37 (new). The compound according to Claim 14 wherein R4 is CH₂N(R8)CONH(R7), and R7 and R8 are both hydrogen.
- 38 (new). The compound according to Claim 1 which is:
- 3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionitrile;
- (Endo)-8-methyl-3-(2,2,2-triphenyl-ethyl)-8-aza-bicyclo[3.2.1]octane;
- 3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionamide;
- 3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionic acid;
- 3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propan-1-ol;
- 1-Ethyl-3-[3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-urea;
- N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-acetamide;
- N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-benzamide;
- 3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-di-thiophen-2-yl-propionitrile;
- N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-benzenesulfonamide;
- [3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-urea; and
- N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-methanesulfonamide.
- 39 (new). The compound which is 3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionitrile.
- 40 (new). A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier or diluent.
- 41 (new). A pharmaceutical composition comprising a compound according to Claim 14 and a pharmaceutically acceptable carrier or diluent.

- 42 (new). A pharmaceutical composition comprising a compound according to Claim 38 and a pharmaceutically acceptable carrier or diluent.
- 43 (new). A pharmaceutical composition comprising a compound according to Claim 39 and a pharmaceutically acceptable carrier or diluent.
- 44 (new). A pharmaceutical composition comprising 3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionitrile and a pharmaceutically acceptable carrier or diluent.